

Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer

Information for the public

Published: 15 January 2020

www.nice.org.uk

Palbociclib (Ibrance), with fulvestrant, is available through the [Cancer Drugs Fund](#). It is a possible option for adults who have locally advanced or metastatic breast cancer that:

- is hormone receptor-positive and human epidermal growth factor 2 (HER2)-negative and
- has been treated with endocrine therapy previously and
- if exemestane plus everolimus would be the most appropriate alternative to a cyclin-dependent kinase 4 and 6 inhibitor.

More evidence on palbociclib is being collected, until August 2021. After this NICE will decide whether or not to recommend it for use on the NHS and update the guidance. It will be available through the Cancer Drugs Fund until then.

If you are not eligible for palbociclib but are already taking it, you should be able to continue until you and your doctor decide when best to stop.

Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

Information and support

The [NHS website](#) may be a good place to find out more.

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0808 800 6000
- [Cancer Research UK](#), 0808 800 4040
- [Macmillan Cancer Support](#), 0808 808 0000

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-3650-2